Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Audrey Anna Bolyard

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Seminars in Hematology|April 17, 2002
Cyclic neutropeniaDavid C Dale, Audrey Anna Bolyard, Andrew Aprikyan
Expert Review of Hematology|November 18, 2023
The promise of novel treatments for severe chronic neutropeniaDavid C Dale, Audrey Anna Bolyard, Vahagn Makaryan
Journal of Cellular Immunology|January 27, 2025
Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for <i>ELANE</i> Associated NeutropeniaVahagn Makaryan, Merideth Kelley, Audrey Anna Bolyard, et al.
Current Opinion in Hematology|November 26, 2019
Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International RegistryDavid C Dale, Audrey Anna Bolyard, Laurie A Steele, et al.
The Journal of Pediatrics|June 2, 2006
Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutationsLaurence A Boxer, Steven Stein, Danielle Buckley, et al.
Current Opinion in Hematology|October 26, 2019
Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndromeDavid C Dale, Emily Dick, Merideth Kelley, et al.
British Journal of Haematology|June 29, 2026
Diagnosis and management of neutropenia in adults: Expert guidanceKarl Welte, Cornelia Zeidler, Julia Skokowa, et al.
Journal of Leukocyte Biology|July 30, 2017
Elastase inhibitors as potential therapies for <i>ELANE</i>-associated neutropeniaVahagn Makaryan, Merideth L Kelley, Breanna Fletcher, et al.
Journal of Cellular Immunology|September 18, 2025
Modeling <i>TCIRG1</i> Neutropenia by Utilizing Patient Derived Induced Pluripotent Stem CellsVahagn Makaryan, Merideth L Kelley, Audrey Anna Bolyard, et al.
Blood|August 13, 2011
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndromeDavid C Dale, Audrey Anna Bolyard, Merideth L Kelley, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Seminars in Hematology|April 17, 2002
Cyclic neutropeniaDavid C Dale, Audrey Anna Bolyard, Andrew Aprikyan
Expert Review of Hematology|November 18, 2023
The promise of novel treatments for severe chronic neutropeniaDavid C Dale, Audrey Anna Bolyard, Vahagn Makaryan
Journal of Cellular Immunology|January 27, 2025
Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for <i>ELANE</i> Associated NeutropeniaVahagn Makaryan, Merideth Kelley, Audrey Anna Bolyard, et al.
Current Opinion in Hematology|November 26, 2019
Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International RegistryDavid C Dale, Audrey Anna Bolyard, Laurie A Steele, et al.
The Journal of Pediatrics|June 2, 2006
Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutationsLaurence A Boxer, Steven Stein, Danielle Buckley, et al.
Current Opinion in Hematology|October 26, 2019
Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndromeDavid C Dale, Emily Dick, Merideth Kelley, et al.
British Journal of Haematology|June 29, 2026
Diagnosis and management of neutropenia in adults: Expert guidanceKarl Welte, Cornelia Zeidler, Julia Skokowa, et al.
Journal of Leukocyte Biology|July 30, 2017
Elastase inhibitors as potential therapies for <i>ELANE</i>-associated neutropeniaVahagn Makaryan, Merideth L Kelley, Breanna Fletcher, et al.
Journal of Cellular Immunology|September 18, 2025
Modeling <i>TCIRG1</i> Neutropenia by Utilizing Patient Derived Induced Pluripotent Stem CellsVahagn Makaryan, Merideth L Kelley, Audrey Anna Bolyard, et al.
Blood|August 13, 2011
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndromeDavid C Dale, Audrey Anna Bolyard, Merideth L Kelley, et al.
Pageof 3